Upcoming AWS Coverage on GlaxoSmithKline

LONDON, UK / ACCESSWIRE / April 18, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY) ("BMS") as the Company and Nordic Bioscience announced a collaboration agreement on April 17, 2017, to develop biomarker technology to potentially assist in the diagnosis and monitoring of fibrotic diseases, including Non-alcoholic steatohepatitis (NASH). Currently, about 20 million patients in the US have NASH, and there are no approved pharmacological treatments as of now. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

One of Bristol-Myers Squibb's competitors within the Drug Manufacturers - Major space, GlaxoSmithKline PLC (NYSE: GSK), is estimated to report earnings on April 26, 2017. AWS will be initiating a research report on GlaxoSmithKline following the release of its next earnings results.

Today, AWS is promoting its blog coverage on BMY; touching on GSK. Get all of our free blog coverage and more by clicking on the link below: http://www.activewallst.com/register/.

Fibrosis Biomarker Technology

Fibrosis is the buildup of scar tissue that impacts organ function. The disease may lead to liver fibrosis, cirrhosis, or idiopathic pulmonary fibrosis, a progressive lung disease with high mortality rate. Nordic has an active portfolio of multiple solutions for prediction of risk of progression and helps to access and manage fibrotic diseases. The disease activity biomarkers offer a toolbox for drug developers, in an attempt to identify patients most suitable for intervention.

Fibrosis is one of the BMS's five therapeutic areas of focus, along with oncology, immunoscience, cardiovascular, and genetically defined diseases caused by abnormalities in the genome. The pipeline from BMS includes six pipeline candidates for fibrotic diseases as of January 01, 2017.

Three of the six of BMS's pipeline candidates are in Phase II development: BMS-986020, a small molecule lysophosphatidic acid 1 (LPA1) receptor antagonist; a recombinant human pentraxin-2 protein candidate for idiopathic pulmonary fibrosis and myelofibrosis that BMS acquired in FY16 for up to $1.25 billion; and another biologic, PEG-FGF21 (pegylated human fibroblast growth factor 21), licensed by the Company from Ambrx in 2011.

Nordic's Biomarker Portfolio

Nordic Bioscience maintains a portfolio of more than 50 biomarkers and has specialized in measurement, development, and validation of assays for collagens, elatins, and laminins as biomarkers of extracellular matrix (ECM) activity. The Company additionally invented C-terminal telopeptide (CTX), a biomarker that noninvasively identifies osteoporosis patients with a high rate of bone loss and can be used to assess response to osteoporosis therapy.

The partnership is designed to combine Nordic's more than 25 years' expertise in biomarker development and clinical trials, focusing extensively on fibrosis as well as rheumatology, with BMS drug-development efforts. Under the collaboration, the Companies have agreed to develop translational biomarkers and diagnostics for NASH in preclinical models of fibrotic diseases, as well as in clinical settings.

BMS Portfolio

BMS announced on July 15, 2015, an agreement for translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis, and idiopathic pulmonary fibrosis. The agreement included studies designed to improve the mechanistic understanding of fibrosis and explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.

The Company acquired Promedior, Inc., and its Novel PRM-151 on August 31, 2015, in development for fibrotic diseases. PRM-151 was the lead asset of Promedior's portfolio and was a recombinant form of human pentraxin-2 protein in Phase 2 development for the treatment of idiopathic pulmonary fibrosis and myelofibrosis. Total aggregate payments for the agreement had a potential to reach $1.25 billion, including an upfront cash payment for the right to acquire Promedior.

Stock Performance

At the close of trading session on Monday, April 17, 2017, Bristol-Myers Squibb's stock price rose slightly by 0.23% to end the day at $52.95. A total volume of 6.47 million shares were exchanged during the session. The Company's share price has gained 6.86% in the past six months. The Company's shares are trading at a PE ratio of 19.93 and have a dividend yield of 2.95%. Furthermore, the stock currently has a market cap of $87.24 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street